EMPOWER-HER for metastatic HER2+ Breast Cancer

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician?s choice chemotherapy compared to trastuzumab in combination with physician?s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Principal Investigator
Headshot of Rani Bansal
Assistant Professor of Medicine
Protocol Number
IRB: PRO00116169
NCT: NCT06435429
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL